Kangrin and Boqe Pharmaceutical Private Limited

Kangrin and Boqe Pharmaceutical Private Limited - pharma in Thane, Maharashtra, India. FY 2026 financials & compliance.
CIN U24231MH2003PTC143320 Incorporated 28 November 2003 ROC Mumbai HQ Thane, Maharashtra, India
Active Private Limited Company pharma MSME
Revenue · FY 2024
₹12.19 Cr
▲ 39% YoY
Net profit · FY 2024
₹8.69 Lakh
Net margin 0.7%
EBITDA · FY 2024
₹12.81 Lakh
EBITDA margin 1.1%
Authorised capital
₹5 Lakh
Registered with MCA
Paid-up capital
₹5 Lakh
Issued & subscribed
Open charges
₹4 Cr
Secured borrowings
Company age
23 yrs
Est. 2003
Directors on board
3
As per MCA filings

About Kangrin and Boqe Pharmaceutical Private Limited

Data last updated:

Kangrin and Boqe Pharmaceutical Private Limited is a private limited company based in Thane, Maharashtra, India. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 28 November 2003 and has been in existence for over 23 years.

The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24231MH2003PTC143320. Its GSTIN is 27AABCL0455G2ZQ (Maharashtra). The company holds 3 GST registrations, of which 2 are active.

The company has an authorised share capital of ₹5 Lakh and a paid-up capital of ₹5 Lakh. It is led by directors including Sudip Paul and Ashish Shrimanth Ghosh.

Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at 212 Blossom Chsraheja Complex Kalyan West, Thane, Maharashtra, India.

As per the financials filed for FY 2024, the company reported a revenue of ₹12.19 Cr, a growth of 39% compared to the previous year. For the same year it recorded a net profit of ₹8.69 Lakh (net margin 0.7%) and EBITDA of ₹12.81 Lakh (EBITDA margin 1.1%). Revenue has grown at a compounded annual rate (CAGR) of 252% over three years and 216% over five years.

As per MCA filings, the company has open charges of ₹4 Cr on record. Court records list 2 cases involving the company, including 2 filed by the company.

Kangrin and Boqe Pharmaceutical Private Limited is registered as an MSME under the Udyam registration framework (Reg. No. UDYAM-MH-33-0181756). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website loguslabortriesindia.co.in.

Company details

CIN U24231MH2003PTC143320
Registration Number 143320
Incorporation Date 28 November 2003
ROC Mumbai
Listing Status Unlisted
Company Status Active
Compliance Status Active Compliant
MSME Classification MSME
Udyam Registration UDYAM-MH-33-0181756

Recognitions & Rankings of Kangrin and Boqe Pharmaceutical

MSME (Udyam registered) Ministry of MSME
Udyam number
UDYAM-MH-33-0181756

Contact details

Kangrin and Boqe Pharmaceutical Private Limited's registered office is in Thane, Maharashtra. Its website is loguslabortriesindia.co.in. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Registered Address
    212 Blossom Chsraheja Complex Kalyan West, Thane, Maharashtra, India
  • Industry
    Pharma, API Manufacturers, Drug Formulation & Development

To see the full contact details of Kangrin and Boqe Pharmaceutical Private Limited, buy the company report.

Comprehensive company report
Kangrin and Boqe Pharmaceutical Private Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Business activity

The main business activity of Kangrin and Boqe Pharmaceutical is trade. In detail, this covers wholesale trading.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
GTradeG1Wholesale Trading

To see the full business activity and turnover split of Kangrin and Boqe Pharmaceutical Private Limited, buy the company report.

Financials of Kangrin and Boqe Pharmaceutical Private Limited

FY 2024 filings available

Kangrin and Boqe Pharmaceutical Private Limited reported revenue of ₹12.19 Cr (up 39% YoY) for FY 2024.

Revenue · FY 2024
₹12.19 Cr ▲ 39%
Net profit · FY 2024
₹8.69 Lakh margin 0.7%
EBITDA · FY 2024
₹12.81 Lakh margin 1.1%

Compounded Annual Growth Rate (CAGR)

Revenue CAGR growth
1 year
▲ 39%
3 years · compounded
▲ 252%
5 years · compounded
▲ 216%
EBITDA CAGR growth
1 year
▲ 112%
3 years · compounded
▲ 62%
5 years · compounded
▲ 198%

Revenue has grown at a compounded annual rate (CAGR) of 216% over five years, including 39% growth in the latest year. EBITDA rose 112% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.

Financial Statement Summary

MetricsFY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Profit and Loss Statement
Revenue from Operations
Other Income
Total Revenue
Cost of Materials Consumed
Employee Benefit Expense
Finance Costs
Depreciation and Amortisation
Other Expenses
Total Expenses
EBITDA₹12.81 Lakh
Profit Before Tax
Tax Expense
Net Profit (PAT)₹8.69 Lakh
Balance Sheet
Share Capital
Reserves and Surplus
Net Worth (Total Equity)
Long-term Borrowings
Short-term Borrowings
Trade Payables
Total Liabilities
Fixed Assets
Investments
Inventories
Trade Receivables
Cash and Bank Balance
Total Assets

Financial Ratios

MetricsFY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Profitability
EBITDA Margin1.1%
Net Profit Margin0.7%
Return on Equity (ROE)
Return on Capital Employed (ROCE)
Return on Assets (ROA)
Liquidity and Debt
Current Ratio
Quick Ratio
Debt-to-Equity Ratio
Interest Coverage Ratio
Efficiency and Growth
Asset Turnover
Receivable Days
Payable Days
Inventory Days
Revenue Growth
Net Profit Growth

To see the full financial statements and ratios of Kangrin and Boqe Pharmaceutical Private Limited, buy the company report.

Board of directors of Kangrin and Boqe Pharmaceutical Private Limited

Kangrin and Boqe Pharmaceutical has 3 current directors and 7 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Sudip PaulDirector28 Nov 200322 Years 11 MonthsCurrent
Ashish Shrimanth GhoshDirector25 Jan 20215 Years 9 MonthsCurrent
Nilesh Pravin LokhandeAdditional Director20 May 20251 Years 5 MonthsCurrent

Peer comparison

Kangrin and Boqe Pharmaceutical Private Limited is compared with the 5 companies closest to it by revenue in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Vesta Pharmachem Private Limited₹12.29 Cr (FY 2025)-9.0%Surat, Gujarat, India
Madhav Nirman Private Limited₹12.26 Cr (FY 2025)26.0%Dehradun, Uttarakhand, India
Kangrin and Boqe Pharmaceutical Private Limitedthis company₹12.19 Cr (FY 2024)₹8.69 Lakh0.7%39.0%Thane, Maharashtra, India
Shilasagaram Enterprises Private Limited₹12.18 Cr (FY 2024)-9.0%Hyderabad, Telangana, India
Slava Therapeutics Private Limited₹12.14 Cr (FY 2020)138.0%Hyderabad, Telangana, India
Nandan Pharma Private Limited₹12.12 Cr (FY 2024)8.0%Thane, Maharashtra, India

To see the full peer comparison of Kangrin and Boqe Pharmaceutical Private Limited, buy the company report.

Auditor

Kangrin and Boqe Pharmaceutical Private Limited is audited by Girish Tanwani & Associates for the financial year 2023.

Auditor firmFinancial yearFirm registration number
Girish Tanwani & AssociatesFY 2023145240

Shareholding

The shareholding of Kangrin and Boqe Pharmaceutical Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.

Shareholder categoryFY 2023FY 2022FY 2021FY 2020FY 2019
Promoters
Domestic institutional investors (DII)
Foreign institutional investors (FII)
Public
Others

To see the full shareholding pattern of Kangrin and Boqe Pharmaceutical Private Limited, buy the company report.

Charges & borrowings

Open charges
₹4 Cr
Satisfied charges
None
Breakdown by lending institutions
Canara Bank₹4.00 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
20 Jun 2025101139261Canara Bank₹4 CrOpen

Total charge records: 1 View all charges

MSME payment delays

No delayed payments to MSME suppliers are on our record for Kangrin and Boqe Pharmaceutical Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.

Employees & EPFO

Kangrin and Boqe Pharmaceutical Private Limited has 1 active EPFO establishment as of Nov 18, 2026.

Active EPFO establishments
1

GST

Kangrin and Boqe Pharmaceutical has 3 GST registrations: 2 active and 1 cancelled or inactive.

Total GSTINs
3
Active
2
Cancelled / inactive
1
GSTINStateStatusRegistered on
27AABCL0455G2ZQMaharashtraActive09 Oct 2023
18AABCL0455G1ZQAssamActive01 Jul 2017

To see the full GST registrations and return filing status of Kangrin and Boqe Pharmaceutical Private Limited, buy the company report.

Recent activity

Kangrin and Boqe Pharmaceutical Private Limited has 10 board changes on record since 2003: 3 appointments and 7 cessations. The latest: Nilesh Pravin Lokhande was appointed as Additional Director on 20 May 2025.

Charges
A charge with Canara Bank amounted to Rs. 400.00 Lakh with Charge ID 101139261 was registered on 20 Jun 2025.
Appointed
Nilesh Pravin Lokhande was appointed as Additional Director.
Ceased
Sudip Paul ceased to be Director.
AGM
Kangrin And Boqe Pharmaceutical Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records.
Filing
Kangrin And Boqe Pharmaceutical Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Mumbai.
Ceased
Samim Noormohmmed Samari ceased to be Director.
Ceased
Golap Talukdar ceased to be Director.
Appointed
Ashish Shrimanth Ghosh was appointed as Director.
Ceased
Pradip Kumar Pal ceased to be Director.
Ceased
Shiba Prosad Sanyal ceased to be Director.
Ceased
Sudip Saha ceased to be Director.
Ceased
Sambhu Nath Paul ceased to be Managing Director.

2 earlier events are in the company report.

Frequently asked questions

Kangrin and Boqe Pharmaceutical is an active private limited company based in Thane, Maharashtra, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 28 November 2003 (23+ years old) and is registered under CIN U24231MH2003PTC143320.

Kangrin and Boqe Pharmaceutical has 3 current directors:

The latest financial statements of Kangrin and Boqe Pharmaceutical on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 September 2024. Year-wise statements from 2015 are in the company report.

The GSTIN of Kangrin and Boqe Pharmaceutical is 27AABCL0455G2ZQ, registered in Maharashtra. The company has 3 GST registrations in all, of which 2 are active and 1 is cancelled or inactive. Other active GSTINs include 18AABCL0455G1ZQ (Assam).

The CIN (Corporate Identification Number) of Kangrin and Boqe Pharmaceutical is U24231MH2003PTC143320. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Kangrin and Boqe Pharmaceutical has 2 court cases on record: 2 filed by the company.

Kangrin and Boqe Pharmaceutical was incorporated on 28 November 2003, making it 23+ years old. It is registered with the Registrar of Companies, Mumbai.

The peers of Kangrin and Boqe Pharmaceutical by revenue are Vesta Pharmachem Private Limited, Madhav Nirman Private Limited, Shilasagaram Enterprises Private Limited, Slava Therapeutics Private Limited, Nandan Pharma Private Limited, all in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading).

Nilesh Pravin Lokhande was appointed as Additional Director on 20 May 2025. Sudip Paul ceased to be Director on 20 May 2025. Samim Noormohmmed Samari ceased to be Director on 01 Feb 2023. Kangrin and Boqe Pharmaceutical has 10 board changes on record in total.

Yes, Kangrin and Boqe Pharmaceutical is registered as an MSME under Udyam registration (number: UDYAM-MH-33-0181756).

Kangrin and Boqe Pharmaceutical can be reached through the website loguslabortriesindia.co.in. Its registered office is in Thane, Maharashtra, India.